Implications of Cannabis Legalization for the US Federal Budget
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.
MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
In a newly released report, MGA highlights the broad economic impact of Otsuka in the United States.
New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases
In a new report, MGA examines the role of rebates among a subset of prescription drugs with the biggest price hikes between 2018 and 2023.
Implications of Cannabis Legalization for the US Federal Budget
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.
New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
In a new white paper, Alex Brill details the consequences of regulatory uncertainty for businesses and provides a close look at the ongoing uncertainty facing companies owned by ESOPs.
MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
MGA latest white paper, by CEO Alex Brill, looks at the role of pharmacy benefit managers (PBMs) in the US prescription drug market.
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
- A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax Reform
- New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
- Congress on the Brink of Disrupting the PBM Market
- Raising the Salt Cap Would Increase Tax Complexity
- Economics of “Delinking” Are Still Not Good
- The Child Tax Credit: Tradeoffs and Preferences
